

Date: 19th March 2025

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051
Scrip Code: 539872	Symbol: BAJAJHCARE

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015

We wish to inform you that Bajaj Healthcare Limited, has received recommendation from Subject Expert Committee (SEC) (Neurology & Psychiatry) of Central Drugs Standard Control Organisation (CDSCO) to conduct Phase III clinical trials for Cenobamate Tablets 12.5mg, 25mg, 50mg, 100mg, 150mg & 200mg.

The press release in this regard, being issued by the Company is hereby submitted for your information.

Kindly acknowledge and take the same on record.

Thanking You,

**For and Behalf of Board of Director of
Bajaj Healthcare Limited**

**Monica Tanwar
Company Secretary & Compliance Officer**



Investor Release

Bajaj Healthcare Limited Secures SEC-CDSCO Nod for Phase III Clinical Trials of Cenobamate Tablets

Mumbai, 19th Mar 2025: Bajaj Healthcare Limited (BHL) is pleased to announce that it has received a recommendation from the Subject Expert Committee (SEC) (Neurology & Psychiatry) of the Central Drugs Standard Control Organisation (CDSCO) to conduct Phase III clinical trials for Cenobamate Tablets in strengths of 12.5mg, 25mg, 50mg, 100mg, 150mg, and 200mg.

Cenobamate is an advanced anti-seizure medication used for the treatment of partial-onset seizures in adults. It functions by regulating excessive neuronal activity, significantly reducing seizure frequency and improving patient outcomes. With this regulatory milestone, Bajaj Healthcare aims to provide a safe and effective treatment option for epilepsy patients in India.

Phase III clinical trials are the final stage of drug development before regulatory approval. These large-scale trials will evaluate the efficacy, safety, and tolerability of Cenobamate Tablets in a diverse patient population. Upon successful completion of the study, Bajaj Healthcare will seek final approval for commercial launch in the Indian market. The API will also be manufactured by the Company.



Speaking at the occasion Mr. Anil Jain, Managing Director, Bajaj Healthcare Limited, said - “We are delighted with this approval from the SEC and look forward to proceeding with the required activities in due course time. Backed by our R&D capabilities and manufacturing infrastructure, we are hopeful to bring Cenobamate to the Indian market. With the rising demand for innovative and effective epilepsy treatments, we remain committed to addressing this critical need with high-quality pharmaceutical solutions.”

About Bajaj Healthcare Ltd:

Bajaj Healthcare Limited a leading Manufacturer of APIs, Intermediates and Formulations. Established in the year 1993, it specializes in manufacturing of intermediates, API, formulations & Nutraceuticals. The Company has state-of-art manufacturing facilities of APIs, intermediates and formulations. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Middle East and South America.



Contact Details

Bajaj Healthcare Ltd	Investor Relations: MUFG Intime India Pvt. Ltd.
	
CIN: L99999MH1993PLC072892	Mr. Irfan Raeen +91 9773778669/ irfan.raeen@in.mpms.mufg.com
Name: Mr. Anil Jain, MD	
Email: : investors@bajajhealth.com	Ms. Prachi Ambre +91 8355985370/ prachi.ambre@in.mpms.mufg.com

Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.